{"id":"W4411643018","doi":"10.1016/j.esmoop.2025.105199","title":"69O Novel regimens for persistent/recurrent rare epithelial ovarian carcinomas (EOCs) selected according to biomarker status: ENGOT-GYN2/GOG-3051/BOUQUET phase II study results","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre; Princess Margaret Cancer Centre; University of Toronto","funders":"Daiichi Sankyo Europe; Defence and Security Accelerator; Takeda Oncology; Genentech; PharmaMar; European Society for Medical Oncology; Eisai; AbbVie; European Commission; Seagen; Merck; Mersana Therapeutics; Amgen; Deciphera Pharmaceuticals; AstraZeneca; Novocure; Regeneron Pharmaceuticals; Sociedad Española de Oncología Médica; Eisai Canada; BeiGene; Clovis Oncology; Pfizer; Incyte; F. Hoffmann-La Roche; Myriad Genetics; Bristol-Myers Squibb; American Society of Clinical Oncology; Vifor Pharma","keywords":"Oncology; Ovarian carcinomas; Biomarker; Ovarian cancer; Internal medicine; Medicine; Phases of clinical research; Epithelial ovarian cancer; Ovarian carcinoma; Biology; Cancer; Toxicity","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006228288,0.0003622959,0.0007864606,0.0004366604,0.0002266186,0.0006755943,0.0003245485,0.0005306855,0.005740884],"category_scores_gemma":[0.0005891398,0.0001474387,0.0007465126,0.0003200172,0.0002511925,0.0003504578,0.0002534807,0.001358235,0.000779],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00075946,"about_ca_system_score_gemma":0.000621537,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001283299,"about_ca_topic_score_gemma":0.006386241,"domain_scores_codex":[0.9997721,0.00009460713,0.00001302335,0.00003301019,0.00003525245,0.00005200964],"domain_scores_gemma":[0.9997059,0.00007287573,0.00005157098,0.00001951299,0.00002512314,0.0001249346],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2496497,0.02069817,0.02263648,0.001928327,0.002297471,0.0003430987,0.0001796565,0.004456459,0.04389123,0.00141689,0.02444421,0.6280583],"study_design_scores_gemma":[0.4483807,0.3258677,0.08798738,0.0005180013,0.002131845,0.001305413,0.0001966601,0.004355144,0.01229701,0.001219524,0.1156494,0.00009119936],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9552678,0.01843709,0.001096695,0.002399282,0.0003742584,0.002144425,0.00541326,0.0001782464,0.01468888],"genre_scores_gemma":[0.9613039,0.00750434,0.004727204,0.003361072,0.000330863,0.001608135,0.01183829,0.00006449205,0.009261799],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005740884,"threshold_uncertainty_score":0.01920515,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06490799290462351,"score_gpt":0.3777180111971781,"score_spread":0.3128100182925546,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}